All Stories

  1. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model

    Article • Antimicrobial Agents and Chemotherapy, May 2018, ASM Journals

    Dr Michael J. Rybak

  2. Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions

    Article • Antimicrobial Agents and Chemotherapy, May 2018, ASM Journals

    Dr Michael J. Rybak

  3. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus , Vancomycin-Intermediate S. aureus (VISA), and Heterog...

    Article • Antimicrobial Agents and Chemotherapy, March 2018, ASM Journals

    Dr Michael J. Rybak

  4. Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations

    Article • Antimicrobial Agents and Chemotherapy, March 2018, ASM Journals

    Dr Michael J. Rybak

  5. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin

    Article • Antimicrobial Agents and Chemotherapy, October 2017, ASM Journals

    Dr Michael J. Rybak

  6. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity

    Article • Antimicrobial Agents and Chemotherapy, September 2017, ASM Journals

    Dr Michael J. Rybak

  7. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

    Article • Antimicrobial Agents and Chemotherapy, November 2016, ASM Journals

    Dr Michael J. Rybak

  8. β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus

    Article • Antimicrobial Agents and Chemotherapy, November 2016, ASM Journals

    Dr. Karl Evans R Henson, Dr Michael J. Rybak

  9. Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in anIn VitroPharmacokinetic-Pharmacodynamic Model

    Article • Antimicrobial Agents and Chemotherapy, July 2016, ASM Journals

    Dr Michael J. Rybak

  10. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

    Article • Antimicrobial Agents and Chemotherapy, July 2016, ASM Journals

    Dr Michael J. Rybak

  11. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in anIn Vitro, Hollow-Fiber Model

    Article • Antimicrobial Agents and Chemotherapy, April 2016, ASM Journals

    Dr Michael J. Rybak

  12. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

    Article • Antimicrobial Agents and Chemotherapy, February 2016, ASM Journals

    Dr Michael J. Rybak

  13. Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models

    Article • Antimicrobial Agents and Chemotherapy, June 2015, ASM Journals

    Dr Michael J. Rybak

  14. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in anIn VitroPharmacokinetic/Pharmacodynamic Model

    Article • Antimicrobial Agents and Chemotherapy, May 2015, ASM Journals

    Dr Michael J. Rybak

  15. β-Lactams Enhance Daptomycin Activity against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium inIn VitroPharmacokinetic/Pharmacodynamic Models

    Article • Antimicrobial Agents and Chemotherapy, March 2015, ASM Journals

    Dr Michael J. Rybak

  16. Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis

    Article • Antimicrobial Agents and Chemotherapy, March 2015, ASM Journals

    Dr Michael J. Rybak

  17. Impact of the Combination of Daptomycin and Trimethoprim-Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant Staphylococcus aureus Infections

    Article • Antimicrobial Agents and Chemotherapy, January 2015, ASM Journals

    Dr Michael J. Rybak

  18. Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E. faecalis

    Article • Antimicrobial Agents and Chemotherapy, June 2014, ASM Journals

    Dr Michael J. Rybak

  19. Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus

    Article • Antimicrobial Agents and Chemotherapy, June 2014, ASM Journals

    Dr Michael J. Rybak

  20. Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in anIn VitroPharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations

    Article • Antimicrobial Agents and Chemotherapy, March 2014, ASM Journals

    Dr Michael J. Rybak

  21. A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus

    Article • Antimicrobial Agents and Chemotherapy, March 2014, ASM Journals

    Dr Michael J. Rybak

  22. Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy

    Article • Antimicrobial Agents and Chemotherapy, February 2014, ASM Journals

    Dr Michael J. Rybak

  23. Ceftaroline plus Avibactam Demonstrates Bactericidal Activity against Pathogenic Anaerobic Bacteria in a One-CompartmentIn VitroPharmacokinetic/Pharmacodynamic Model

    Article • Antimicrobial Agents and Chemotherapy, November 2013, ASM Journals

    Dr Michael J. Rybak

  24. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection

    Article • Antimicrobial Agents and Chemotherapy, June 2013, ASM Journals

    Dr Michael J. Rybak

  25. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections

    Article • Antimicrobial Agents and Chemotherapy, June 2013, ASM Journals

    Dr Michael J. Rybak

  26. Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods

    Article • Journal of Clinical Microbiology, April 2013, ASM Journals

    Dr Michael J. Rybak

  27. Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in anIn VitroPharmacokinetic/Pharmacodynamic Model: Exploring the “Seesaw Effect”

    Article • Antimicrobial Agents and Chemotherapy, April 2013, ASM Journals

    Dr Michael J. Rybak

  28. Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA

    Article • Antimicrobial Agents and Chemotherapy, February 2013, ASM Journals

    Dr Michael J. Rybak

  29. Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model

    Article • Antimicrobial Agents and Chemotherapy, October 2012, ASM Journals

    Dr Michael J. Rybak